Related Experiment Video
Updated: Mar 3, 2026
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
1.3K
Hepatitis E during lenalidomide treatment for multiple myeloma in complete remission
1Department of Internal Medicine, Rode Kruis Hospital, Beverwijk, the Netherlands.
The Netherlands Journal of Medicine
|May 5, 2017
Summary
Lenalidomide improves multiple myeloma survival but can cause side effects. This case highlights hepatitis E as a potential cause of liver issues during lenalidomide therapy.
Area of Science:
- Hepatology
- Oncology
- Infectious Diseases
Background:
- Lenalidomide is a key treatment for multiple myeloma, enhancing patient survival.
- Chemotherapeutic agents, including lenalidomide, are associated with various adverse effects.
- Multiple myeloma patients often undergo immunosuppressive therapy, increasing infection risks.
Observation:
- A patient with multiple myeloma in complete remission developed liver abnormalities during lenalidomide treatment.
- This represents the first documented instance of hepatitis E infection occurring concurrently with lenalidomide therapy in this patient population.
Findings:
- Hepatitis E virus (HEV) infection was diagnosed in the patient undergoing lenalidomide treatment.
- The clinical presentation suggests a possible link between lenalidomide therapy and the manifestation of hepatitis E.
Implications:
- Hepatitis E should be considered in the differential diagnosis of liver enzyme abnormalities in patients treated with lenalidomide.
- Awareness of this potential complication may guide timely diagnosis and management in similar cases.
- Further investigation may be warranted to understand the interaction between lenalidomide and hepatitis E.
Related Concept Videos
01:26Diseases of the Liver and Gallbladder
2.2K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.2K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
317
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
317
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
289
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
289
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
244
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
244
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
317
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
317
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K